4//SEC Filing
Saad Kareem 4
Accession 0001415889-24-008502
CIK 0001818331other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:14 PM ET
Size
9.8 KB
Accession
0001415889-24-008502
Insider Transaction Report
Form 4
Saad Kareem
Chief Business Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2024-03-16+5,114→ 31,525 total - Sale
Class A Common Stock
2024-03-18$10.59/sh−2,008$21,269→ 29,517 total - Exercise/Conversion
Restricted Stock Unit
2024-03-16−5,114→ 61,362 total→ Class A Common Stock (5,114 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F2]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Documents
Issuer
GeneDx Holdings Corp.
CIK 0001818331
Entity typeother
Related Parties
1- filerCIK 0001873805
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 4:14 PM ET
- Size
- 9.8 KB